Category Archives: cancer

Novel PEG hydrogel as 3D synthetic extracellular matrix (ECM) for organoid culture

Posted on December 31, 2016 by Creative PEGWorks

A recent article published in the leading scientific journal of Nature (Designer matrices for intestinal stem cell and organoid culture, Matthias P. Lutolf et al from the Ecole Polytechnique Fédérale de Lausanne (EPFL) in Switzerland, Nature, Published online 16 November 2016,  … Continue reading →

Posted in Blogs, cancer, Regenerative medicine | 1 Comment

PEGfilgrastim (Neulasta) Approved for Treatment of Acute Radiation Syndrome

Posted on September 23, 2016 by Creative PEGWorks

In November 2015, the Food and Drug Administration approved the use of Amgen’s pegfilgrastim (Neulasta) to increase survival of people acutely exposed to high-dose radiation that damages the bone marrow, which will improve access to the drug in the event … Continue reading →

Posted in Biologic, Blogs, cancer, chemotherapy | Leave a comment

The next stop for PEGylated protein drugs: Biosimilar

Posted on September 23, 2016 by Creative PEGWorks

Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor analog filgrastim. It serves to stimulate the level of white blood cells. Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim … Continue reading →

Posted in Biologic, Biosimilar, Blogs, cancer, chemotherapy, pegylation | Leave a comment

Can a PEGylated protein be ever considered a Biosimilar drug?

Posted on March 27, 2015 by Creative PEGWorks

In March 2015, the FDA approved the first biosimilar drug for use in the United States. The drug called Zarxio, produced by Sandoz, is used to help prevent infections in cancer patients receiving chemotherapy, and it is a biosimilar alternative … Continue reading →

Posted in Biologic, Biosimilar, Blogs, cancer, chemotherapy, pegylation, PEGylation Reagents | Tagged , , , , , , | Leave a comment